Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson Full-Year Guidance by Quarter
Full-Year Guidance — Adjusted diluted EPS growth midpoint (%) (%)
Johnson & Johnson Full-Year Guidance: 2.9% in Q3 2026, down 5.8 pts from a year earlier.
Latest, Q3 2026
2.9%
Period ended Sep 30, 2026
Change on a year earlier
-5.8 pts
8.7% in Q3 2025
History
17 quarters
Since Q3 2022
Sources
17
Documents cited below
Where the Q3 2026 figure comes from
“|| Adjusted EPS (Diluted) 3,4 / Mid-point Change vs. Prior Year / Mid-point | $11.05 – $11.15 / $11.10 2.4% – 3.3% / 2.9% | $10.96 – $11.11 / $11.04 1.6% – 3.0% / 2.3%”
Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Reported in Form 8-K EX-99.1 Full-Year Guidance Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Johnson & Johnson Full-Year Guidance (%), quarterly Q3 2022–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/guid-adj-eps-growth-mid-pct
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.